Skip to content

Clinical Trial to Assess the Efficacy and Safety of EASYDEW MD REGEN Cream Containing Neopop-S.

Clinical Trial to Assess the Efficacy and Safety of Neopop-S Containing EASYDEW

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05982509
Enrollment
20
Registered
2023-08-08
Start date
2022-11-11
Completion date
2023-07-27
Last updated
2023-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laser-Induced Scar

Brief summary

The purpose of this clinical study is to evaluate the effect on skin regeneration after applying EasyDew MD Regen Cream containing Neopep-S, a regeneration factor, to patients who have undergone picosure picosure laser skin treatment as needed.

Detailed description

This clinical study is a researcher-led randomized control group comparative clinical study that is conducted prospectively for one month after applying medical devices for clinical research. The subjects are those who have undergone a picosure laser procedure for therapeutic purposes on the skin tissue of the face or body, and a screening test is conducted after the subject (and/or legal representative) agrees in writing to participate in the clinical study. The screening test results are evaluated, and subjects who meet the selection criteria and do not meet the exclusion criteria are registered in clinical research. Participating subjects are randomly assigned to the control group and the study group using a random number table at a 5:5 ratio. * Control group: 10 people without treatment * Study Group: 10 People Applying EasyDu Regen MD Cream Clinical study subjects are randomly assigned to control and study groups. In the case of the study group, the Easy Dew Regen MD cream provided through prescription is applied twice a day (morning and evening) to the skin of the area where the picosure laser treatment has been performed and absorbed well. The control group is the non-chalant group. However, general moisturizers that were used at home rather than medical devices for one month after the procedure can be used, and they are applied twice a day (morning and evening) to the skin of the area where the laser treatment has been performed and absorbed well. One month of clinical research medical device application will be observed, and subjects will regularly visit the research institution to evaluate its validity and safety during screening visits (Visit1), treatment (Visit2), 2 weeks after treatment (Visit3), and 1 month after treatment (Visit3) You will receive it.

Interventions

DEVICEEasyDew Regen MD Cream

For the study group, I received the prescription Easy Dew Regen MD Cream from Picosure Laser Apply an appropriate amount twice a day (morning and evening) to the skin of the area so that it can be absorbed well do. The control group is the non-chalant group. However, for one month after the procedure, it is not a medical device The normal moisturizer you use at home is available, and the area where you have undergone laser treatment Apply it twice a day (morning and evening) to the skin so that it can be absorbed well.

Sponsors

Eun-ji Kim
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Those aged 19 to 65 who have undergone picosure laser treatment on facial and body skin tissues * Decided to participate in this clinical study and signed a written informed consent the subject

Exclusion criteria

* Subjects with uncontrolled diabetes * Subjects with uncontrolled hypertension and cardiovascular disease * Subjects with hemorrhagic diseases such as hemophilia * Immunosuppressants, corticosteroids, cytotoxic agents, and anticoagulants can affect the results Subjects who are or are scheduled to receive medication for an extended period of time * Acute or chronic skin disease causes stage progression or active bacteria in the application area Who has a virus infection * When the researcher's judgment determines that participation in the study is inappropriate (e.g. keloid constitution)

Design outcomes

Primary

MeasureTime frameDescription
Transepidermal water loss Transcutaneous water loss (TEWL) measuredBefore, immediately after treatment, and one month after applicationBefore, immediately after treatment, and one month after application of the medical device Transcutaneous water loss (TEWL) measured

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026